EADV24: Novo’s semaglutide shows potential in chronic skin condition in obese patients - Endpoints News

A small study conducted by researchers at St. Vincent's University Hospital in Dublin suggests that Novo Nordisk's GLP-1 semaglutide could treat a common and chronic skin condition called hidradenitis suppurativa. The study, published Wednesday at the EurAds Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute